Genmab Says Johnson & Johnson Declines Global License Option for HexaBody-CD38; Shares Fall

MT Newswires Live03-10

Genmab (GMAB) said Monday that Johnson & Johnson (JNJ) has chosen not to exercise its option for a global license to develop, produce, and market HexaBody-CD38.

Although the initial HexaBody-CD38 clinical data demonstrated strong efficacy, Genmab has decided not to proceed with further development after evaluating the data, market landscape, and portfolio priorities, the biotechnology company said.

Under the development and option agreement between the companies for HexaBody-CD38, Genmab supplied Johnson & Johnson with data from a clinical proof-of-concept study in multiple myeloma, which included a head-to-head comparison with Darzalex Faspro, the company said.

Shares of Genmab were down more than 7% in recent Monday trading.

Price: 22.23, Change: -1.92, Percent Change: -7.93

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2518769512?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-10 22:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518769512","market":"fut","top_or_hot":-1,"title":"Genmab Says Johnson & Johnson Declines Global License Option for HexaBody-CD38; Shares Fall","media":"MT Newswires Live","content":"<html><body><p> Genmab (GMAB) said Monday that Johnson &amp; Johnson (JNJ) has chosen not to exercise its option for a global license to develop, produce, and market HexaBody-CD38.</p><p>Although the initial HexaBody-CD38 clinical data demonstrated strong efficacy, Genmab has decided not to proceed with further development after evaluating the data, market landscape, and portfolio priorities, the biotechnology company said.</p><p>Under the development and option agreement between the companies for HexaBody-CD38, Genmab supplied Johnson &amp; Johnson with data from a clinical proof-of-concept study in multiple myeloma, which included a head-to-head comparison with Darzalex Faspro, the company said.</p><p>Shares of Genmab were down more than 7% in recent Monday trading.</p><p>Price: 22.23, Change: -1.92, Percent Change: -7.93</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genmab Says Johnson & Johnson Declines Global License Option for HexaBody-CD38; Shares Fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenmab Says Johnson & Johnson Declines Global License Option for HexaBody-CD38; Shares Fall\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-10 22:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Genmab (GMAB) said Monday that Johnson &amp; Johnson (JNJ) has chosen not to exercise its option for a global license to develop, produce, and market HexaBody-CD38.</p><p>Although the initial HexaBody-CD38 clinical data demonstrated strong efficacy, Genmab has decided not to proceed with further development after evaluating the data, market landscape, and portfolio priorities, the biotechnology company said.</p><p>Under the development and option agreement between the companies for HexaBody-CD38, Genmab supplied Johnson &amp; Johnson with data from a clinical proof-of-concept study in multiple myeloma, which included a head-to-head comparison with Darzalex Faspro, the company said.</p><p>Shares of Genmab were down more than 7% in recent Monday trading.</p><p>Price: 22.23, Change: -1.92, Percent Change: -7.93</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2518769512","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518769512","pubTimestamp":1741618733,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Genmab  said Monday that Johnson & Johnson  has chosen not to exercise its option for a global license to develop, produce, and market HexaBody-CD38.Although the initial HexaBody-CD38 clinical data demonstrated strong efficacy, Genmab has decided not to proceed with further development after evaluating the data, market landscape, and portfolio priorities, the biotechnology company said.Under the development and option agreement between the companies for HexaBody-CD38, Genmab supplied Johnson & Johnson with data from a clinical proof-of-concept study in multiple myeloma, which included a head-to-head comparison with Darzalex Faspro, the company said.Shares of Genmab were down more than 7% in recent Monday trading.Price: 22.23, Change: -1.92, Percent Change: -7.93","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Genmab表示强生拒绝HexaBody-CD38的全球许可选项；股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMAB":0.9,"JNJ":1},"content_text":"Genmab (GMAB) said Monday that Johnson & Johnson (JNJ) has chosen not to exercise its option for a global license to develop, produce, and market HexaBody-CD38.Although the initial HexaBody-CD38 clinical data demonstrated strong efficacy, Genmab has decided not to proceed with further development after evaluating the data, market landscape, and portfolio priorities, the biotechnology company said.Under the development and option agreement between the companies for HexaBody-CD38, Genmab supplied Johnson & Johnson with data from a clinical proof-of-concept study in multiple myeloma, which included a head-to-head comparison with Darzalex Faspro, the company said.Shares of Genmab were down more than 7% in recent Monday trading.Price: 22.23, Change: -1.92, Percent Change: -7.93","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2518769512"}